| Literature DB >> 28279468 |
Stephen G Chun1, Heath D Skinner2, Bruce D Minsky2.
Abstract
The treatment of locally advanced esophageal cancer is controversial. For patients who are candidates for surgical resection, multiple prospective clinical trials have demonstrated the advantages of neoadjuvant chemoradiation. For patients who are medically inoperable, definitive chemoradiation is an alternative approach with survival rates comparable to trimodality therapy. Although trials of dose escalation are ongoing, the standard radiation dose remains 50.4 Gy. Modern radiotherapy techniques such as image-guided radiation therapy with motion management and intensity-modulated radiation therapy are strongly encouraged with a planning objective to maximize conformity to the intended target volume while reducing dose delivered to uninvolved normal tissues.Entities:
Keywords: Chemotherapy; Dose-escalation; Esophageal cancer; IMRT; Radiation
Mesh:
Year: 2017 PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN: 1055-3207 Impact factor: 3.495